{
  "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 176 cm,Body weight: 75 kg,BMI: 24.21,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.23,Albumin: 4.7 g/dL,Lymphocyte: 2.17,Neutrophil: 4.27,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: LZTR1,NF1,STK11,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
  "options": {
    "A": "Complete Response",
    "B": "Partial Response",
    "C": "Stable Disease",
    "D": "Progressive Disease"
  },
  "answer_idx": "C",
  "answer": "SD",
  "process_id": 462,
  "options_str": "A. Complete Response\nB. Partial Response\nC. Stable Disease\nD. Progressive Disease",
  "gpt_filter_query": "<Multiple-choice Question>\nPatient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 176 cm,Body weight: 75 kg,BMI: 24.21,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.23,Albumin: 4.7 g/dL,Lymphocyte: 2.17,Neutrophil: 4.27,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: LZTR1,NF1,STK11,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?\nA. Complete Response\nB. Partial Response\nC. Stable Disease\nD. Progressive Disease\nCorrect Answer: SD\n</Multiple-choice Question>\n\nYou are an expert in filtering and evaluating multiple-choice questions for advanced reasoning tasks. Your job is to evaluate a given question and determine whether it meets the following criteria: \n1. **Depth of Reasoning:** The question should require deeper reasoning. If the question appears too simple, mark it as \"Too Simple\".\n2. **Unambiguous Correct Answer:** The question must have a unique and unambiguous correct answer. If the question asks for \"incorrect options\" or allows for multiple correct answers, mark it as \"Ambiguous Answer\".\n3. **Open-Ended Reformulation Feasibility:** The question should be suitable for reformatting into an open-ended format. If the question cannot be easily reformulated into an open-ended problem and a clear ground-truth answer, mark it as \"Not Reformulatable\".\n\nFor each question, provide one of the following evaluations:  \n- \"Pass\" (The question meets all the criteria.)  \n- \"Too Simple\"  \n- \"Ambiguous Answer\"  \n- \"Not Reformulatable\" ",
  "gpt_filter_response": "Pass",
  "gpt_reformat_query": "I will provide you with a multiple-choice question, and your task is to rewrite it into an open-ended question, along with a Ground-True Answer. The requirements are:\n\n1. The question must be specific, targeting the point being tested in the original multiple-choice question. Ensure it is open-ended, meaning no options are provided, but there must be a definitive Ground-True Answer.\n2. Based on the correct answer from the original question, provide a concise Ground-True Answer. The answer should allow for precise matching to determine whether the model's response is correct.\n\nHere is the multiple-choice question for you to rewrite:\n<Multiple-choice Question>\nPatient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 176 cm,Body weight: 75 kg,BMI: 24.21,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.23,Albumin: 4.7 g/dL,Lymphocyte: 2.17,Neutrophil: 4.27,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: LZTR1,NF1,STK11,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?\nA. Complete Response\nB. Partial Response\nC. Stable Disease\nD. Progressive Disease\nCorrect Answer: SD\n</Multiple-choice Question>\n\nPlease output the result in the following JSON format:\n```json\n{\n\"Open-ended Verifiable Question\": \"...\",\n\"Ground-True Answer\": \"...\"\n}\n```",
  "gpt_reformat_response": "```json\n{\n  \"Open-ended Verifiable Question\": \"Based on the clinical profile of a 68-year-old male patient with adenocarcinoma, brain metastasis, EGFR wild-type, ALK-negative, PD-L1 0%, and treated with the chemotherapy regimen of Pemetrexed/Cisplatin, what is the most likely treatment response observed?\",\n  \"Ground-True Answer\": \"Stable Disease\"\n}\n```",
  "Open-ended Verifiable Question": "Based on the clinical profile of a 68-year-old male patient with adenocarcinoma, brain metastasis, EGFR wild-type, ALK-negative, PD-L1 0%, and treated with the chemotherapy regimen of Pemetrexed/Cisplatin, what is the most likely treatment response observed?",
  "Ground-True Answer": "Stable Disease",
  "verify": [
    true
  ],
  "Long_CoT": [
    {
      "action": "Inner Thinking",
      "title": "Understanding the Patient Profile",
      "content": "The patient is a 68-year-old male with a diagnosis of adenocarcinoma, which has metastasized to the brain. The tumor is characterized as EGFR wild-type, ALK-negative, and has a PD-L1 expression of 0%. These molecular characteristics typically exclude targeted therapies such as EGFR or ALK inhibitors and suggest lower likelihood of response to PD-1/PD-L1 inhibitors."
    },
    {
      "action": "Inner Thinking",
      "title": "Evaluating Pemetrexed/Cisplatin Efficacy",
      "content": "Pemetrexed and cisplatin are chemotherapeutic agents commonly used in the treatment of non-small cell lung cancers (NSCLC), including adenocarcinomas. This combination is generally considered a standard first-line therapy for patients without targetable mutations who have good performance status. However, brain metastases can complicate treatment as chemotherapeutic agents may have limited ability to cross the blood-brain barrier."
    },
    {
      "action": "Inner Thinking",
      "title": "Impact of Molecular Profile on Treatment Response",
      "content": "The absence of actionable mutations (EGFR wild-type and ALK-negative) and the low PD-L1 expression (0%) suggest limited options beyond chemotherapy. The impact of low PD-L1 would typically mean less likelihood of success with immunotherapy. Chemotherapy is often effective to an extent but may not result in a durable or complete response, particularly in advanced metastatic settings."
    },
    {
      "action": "Inner Thinking",
      "title": "Expectations for Overall Response",
      "content": "Given the advanced stage with brain metastases and lack of targetable mutations, the patientâ€™s response to the Pemetrexed/Cisplatin regimen might be partial response or stable disease. Complete responses are rare in this context with chemotherapy alone."
    },
    {
      "action": "Final Conclusion",
      "content": "The most likely treatment response for a 68-year-old male with brain metastasis, EGFR wild-type, ALK-negative, and PD-L1 0% when treated with Pemetrexed/Cisplatin chemotherapy is a partial response or stable disease."
    },
    {
      "action": "Verification",
      "content": "Reviewing common outcomes for patients with this profile, those treated solely with chemotherapies like Pemetrexed/Cisplatin often achieve partial responses. The presence of brain metastases and absence of targetable mutations further suggest this conclusion is plausible. Thus, the conclusion holds."
    }
  ],
  "gpt4_query_cot": [
    "<question>\nBased on the clinical profile of a 68-year-old male patient with adenocarcinoma, brain metastasis, EGFR wild-type, ALK-negative, PD-L1 0%, and treated with the chemotherapy regimen of Pemetrexed/Cisplatin, what is the most likely treatment response observed?\n</question>\n\nPlease respond to the above question <question> using the Chain of Thought (CoT) reasoning method. Your response should consist of multiple steps, each of which includes three types of actions: **\"Inner Thinking\"**, **\"Final Conclusion\"**, and **\"Verification\"**:\n\n- **'Inner Thinking'**: This is the step where thinking is done. Note that multiple 'Inner Thinking' steps are required to describe thorough reasoning. Each step should first generate a brief title.\n- **'Final Conclusion'**: At this stage, you summarize the correct reasoning from previous 'Inner Thinking' steps and provide the final answer. No title is required here.\n- **'Verification'**: At this stage, you verify the conclusion from the \"Final Conclusion\" step. If the conclusion holds, end the process. If not, return to \"Inner Thinking\" for further reasoning. No title is required here.\n\nThe output format must strictly follow the JSON structure below:\n```json\n{\n\"CoT\": [\n    {\"action\": \"Inner Thinking\", \"title\": \"...\", \"content\": \"...\"},\n    ...,\n    {\"action\": \"Final Conclusion\", \"content\": \"...\"},\n    {\"action\": \"Verification\", \"content\": \"...\"}\n]\n}\n```",
    "<Model Response>  \nThe most likely treatment response for a 68-year-old male with brain metastasis, EGFR wild-type, ALK-negative, and PD-L1 0% when treated with Pemetrexed/Cisplatin chemotherapy is a partial response or stable disease.  \n</Model Response>  \n\n<Reference Answer>  \nStable Disease\n</Reference Answer>  \n\nYou are provided with a model-generated response (<Model Response>) and a reference answer (<Reference Answer>). Compare the model response with the reference answer and determine its correctness. Your task is to simply output \"True\" if the response is correct, and \"False\" otherwise.",
    "<Thought Process>\n### Understanding the Patient Profile\nThe patient is a 68-year-old male with a diagnosis of adenocarcinoma, which has metastasized to the brain. The tumor is characterized as EGFR wild-type, ALK-negative, and has a PD-L1 expression of 0%. These molecular characteristics typically exclude targeted therapies such as EGFR or ALK inhibitors and suggest lower likelihood of response to PD-1/PD-L1 inhibitors.\n\n### Evaluating Pemetrexed/Cisplatin Efficacy\nPemetrexed and cisplatin are chemotherapeutic agents commonly used in the treatment of non-small cell lung cancers (NSCLC), including adenocarcinomas. This combination is generally considered a standard first-line therapy for patients without targetable mutations who have good performance status. However, brain metastases can complicate treatment as chemotherapeutic agents may have limited ability to cross the blood-brain barrier.\n\n### Impact of Molecular Profile on Treatment Response\nThe absence of actionable mutations (EGFR wild-type and ALK-negative) and the low PD-L1 expression (0%) suggest limited options beyond chemotherapy. The impact of low PD-L1 would typically mean less likelihood of success with immunotherapy. Chemotherapy is often effective to an extent but may not result in a durable or complete response, particularly in advanced metastatic settings.\n\n### Expectations for Overall Response\nGiven the advanced stage with brain metastases and lack of targetable mutations, the patientâ€™s response to the Pemetrexed/Cisplatin regimen might be partial response or stable disease. Complete responses are rare in this context with chemotherapy alone.\n\n### Conclusion\nThe most likely treatment response for a 68-year-old male with brain metastasis, EGFR wild-type, ALK-negative, and PD-L1 0% when treated with Pemetrexed/Cisplatin chemotherapy is a partial response or stable disease.\n\n### Verification\nReviewing common outcomes for patients with this profile, those treated solely with chemotherapies like Pemetrexed/Cisplatin often achieve partial responses. The presence of brain metastases and absence of targetable mutations further suggest this conclusion is plausible. Thus, the conclusion holds.\n</Thought Process>\n\n<Question>\nBased on the clinical profile of a 68-year-old male patient with adenocarcinoma, brain metastasis, EGFR wild-type, ALK-negative, PD-L1 0%, and treated with the chemotherapy regimen of Pemetrexed/Cisplatin, what is the most likely treatment response observed?\n</Question>\n\nThe <Thought Process> above reflects the model's reasoning based on the <Question>. Your task is to rewrite the <Thought Process> to resemble a more human-like, intuitive natural thinking process. The new version should:\n\n1. Be presented as step-by-step reasoning, with each thought on a new line separated by a line break.\n2. Avoid structured titles or formatting, focusing on natural transitions. Use casual and natural language for transitions or validations, such as \"hmm,\" \"oh,\" \"also,\" or \"wait.\"\n3. Expand the content, making the reasoning richer, more detailed, and logically clear while still being conversational and intuitive.\n\nReturn directly the revised natural thinking in JSON format as follows:\n```json\n{\n  \"NaturalReasoning\": \"...\"\n}\n```",
    "<Internal Thinking>\nOkay, so there's this 68-year-old guy dealing with adenocarcinoma which has unfortunately spread to his brain. That's definitely tough. Let's see, his tumor is EGFR wild-type and ALK-negative, which means those fancy EGFR or ALK inhibitors won't work for him. And his PD-L1 expression is 0%, so that tells us the immune checkpoint inhibitors might not be that effective here either. Hmm, not a lot of targeted therapy options available.\n\nAlright, let's think about chemotherapy then. Pemetrexed and cisplatin are pretty common for non-small cell lung cancer folks. They usually use these drugs when there aren't any specific targets to aim for and the person is in good health for treatment. But we have to consider the brain metastases situation, since chemotherapy doesn't always get through the blood-brain barrier effectively.\n\nGiven his molecular profile, we can't really rely on targeted or immune therapies, so chemotherapy might be our mainstay. Oh, right, and his low PD-L1 expression usually means limited success with immunotherapy. So, we're kind of sticking to chemotherapy, trying to manage what we can.\n\nGenerally, with cases like his, achieving a complete response is really rare. Chemotherapy could give him a partial response, you know, like shrink the tumor a bit or at least stop it from growing, or it might keep things stable for a while. There's some hope for improvement but not a cure with just this regimen.\n\nSo, after thinking through all of that, I'd say the most likely response for him with the Pemetrexed/Cisplatin treatment is partial response or maybe stable disease. Let's be honest here; given the spread and those molecular characteristics, we're looking at managing the disease more than anything else.\n</Internal Thinking>\n\n<Question>\nBased on the clinical profile of a 68-year-old male patient with adenocarcinoma, brain metastasis, EGFR wild-type, ALK-negative, PD-L1 0%, and treated with the chemotherapy regimen of Pemetrexed/Cisplatin, what is the most likely treatment response observed?\n</Question>\n\nThe <Internal Thinking> represents your internal thoughts about the <Question>. Based on this, generate a rich and high-quality final response to the user. If there is a clear answer, provide it first. Ensure your final response closely follows the <Question>. The response style should resemble GPT-4's style as much as possible. Output only your final response, without any additional content."
  ],
  "gpt4_response_cot": [
    "```json\n{\n    \"CoT\": [\n        {\n            \"action\": \"Inner Thinking\", \n            \"title\": \"Understanding the Patient Profile\", \n            \"content\": \"The patient is a 68-year-old male with a diagnosis of adenocarcinoma, which has metastasized to the brain. The tumor is characterized as EGFR wild-type, ALK-negative, and has a PD-L1 expression of 0%. These molecular characteristics typically exclude targeted therapies such as EGFR or ALK inhibitors and suggest lower likelihood of response to PD-1/PD-L1 inhibitors.\"\n        },\n        {\n            \"action\": \"Inner Thinking\", \n            \"title\": \"Evaluating Pemetrexed/Cisplatin Efficacy\", \n            \"content\": \"Pemetrexed and cisplatin are chemotherapeutic agents commonly used in the treatment of non-small cell lung cancers (NSCLC), including adenocarcinomas. This combination is generally considered a standard first-line therapy for patients without targetable mutations who have good performance status. However, brain metastases can complicate treatment as chemotherapeutic agents may have limited ability to cross the blood-brain barrier.\"\n        },\n        {\n            \"action\": \"Inner Thinking\", \n            \"title\": \"Impact of Molecular Profile on Treatment Response\", \n            \"content\": \"The absence of actionable mutations (EGFR wild-type and ALK-negative) and the low PD-L1 expression (0%) suggest limited options beyond chemotherapy. The impact of low PD-L1 would typically mean less likelihood of success with immunotherapy. Chemotherapy is often effective to an extent but may not result in a durable or complete response, particularly in advanced metastatic settings.\"\n        },\n        {\n            \"action\": \"Inner Thinking\", \n            \"title\": \"Expectations for Overall Response\", \n            \"content\": \"Given the advanced stage with brain metastases and lack of targetable mutations, the patientâ€™s response to the Pemetrexed/Cisplatin regimen might be partial response or stable disease. Complete responses are rare in this context with chemotherapy alone.\"\n        },\n        {\n            \"action\": \"Final Conclusion\", \n            \"content\": \"The most likely treatment response for a 68-year-old male with brain metastasis, EGFR wild-type, ALK-negative, and PD-L1 0% when treated with Pemetrexed/Cisplatin chemotherapy is a partial response or stable disease.\"\n        },\n        {\n            \"action\": \"Verification\", \n            \"content\": \"Reviewing common outcomes for patients with this profile, those treated solely with chemotherapies like Pemetrexed/Cisplatin often achieve partial responses. The presence of brain metastases and absence of targetable mutations further suggest this conclusion is plausible. Thus, the conclusion holds.\"\n        }\n    ]\n}\n```",
    "True",
    "```json\n{\n  \"NaturalReasoning\": \"Okay, so there's this 68-year-old guy dealing with adenocarcinoma which has unfortunately spread to his brain. That's definitely tough. Let's see, his tumor is EGFR wild-type and ALK-negative, which means those fancy EGFR or ALK inhibitors won't work for him. And his PD-L1 expression is 0%, so that tells us the immune checkpoint inhibitors might not be that effective here either. Hmm, not a lot of targeted therapy options available.\\n\\nAlright, let's think about chemotherapy then. Pemetrexed and cisplatin are pretty common for non-small cell lung cancer folks. They usually use these drugs when there aren't any specific targets to aim for and the person is in good health for treatment. But we have to consider the brain metastases situation, since chemotherapy doesn't always get through the blood-brain barrier effectively.\\n\\nGiven his molecular profile, we can't really rely on targeted or immune therapies, so chemotherapy might be our mainstay. Oh, right, and his low PD-L1 expression usually means limited success with immunotherapy. So, we're kind of sticking to chemotherapy, trying to manage what we can.\\n\\nGenerally, with cases like his, achieving a complete response is really rare. Chemotherapy could give him a partial response, you know, like shrink the tumor a bit or at least stop it from growing, or it might keep things stable for a while. There's some hope for improvement but not a cure with just this regimen.\\n\\nSo, after thinking through all of that, I'd say the most likely response for him with the Pemetrexed/Cisplatin treatment is partial response or maybe stable disease. Let's be honest here; given the spread and those molecular characteristics, we're looking at managing the disease more than anything else.\"\n}\n```",
    "Given the clinical profile described for the 68-year-old male with adenocarcinoma that has metastasized to the brain, along with his molecular characteristicsâ€”EGFR wild-type, ALK-negative, and PD-L1 expression at 0%â€”the most suitable treatment option in this scenario is a chemotherapy regimen, such as Pemetrexed/Cisplatin. Because this patient's cancer lacks actionable mutations or markers that would make targeted therapy or immunotherapy more effective, chemotherapy becomes the main course of action.\n\nThe anticipated response to the Pemetrexed/Cisplatin regimen, taking into account the extent of disease spread and the available treatment limitations, is most likely to be partial response or stable disease. This means that while the treatment may reduce tumor size or slow disease progression, achieving a complete response or cure with this approach is unlikely. The primary goal in this context is disease management, aiming to control tumor growth and maintain the patient's quality of life."
  ],
  "response_struct": [
    [
      {
        "action": "Inner Thinking",
        "title": "Understanding the Patient Profile",
        "content": "The patient is a 68-year-old male with a diagnosis of adenocarcinoma, which has metastasized to the brain. The tumor is characterized as EGFR wild-type, ALK-negative, and has a PD-L1 expression of 0%. These molecular characteristics typically exclude targeted therapies such as EGFR or ALK inhibitors and suggest lower likelihood of response to PD-1/PD-L1 inhibitors."
      },
      {
        "action": "Inner Thinking",
        "title": "Evaluating Pemetrexed/Cisplatin Efficacy",
        "content": "Pemetrexed and cisplatin are chemotherapeutic agents commonly used in the treatment of non-small cell lung cancers (NSCLC), including adenocarcinomas. This combination is generally considered a standard first-line therapy for patients without targetable mutations who have good performance status. However, brain metastases can complicate treatment as chemotherapeutic agents may have limited ability to cross the blood-brain barrier."
      },
      {
        "action": "Inner Thinking",
        "title": "Impact of Molecular Profile on Treatment Response",
        "content": "The absence of actionable mutations (EGFR wild-type and ALK-negative) and the low PD-L1 expression (0%) suggest limited options beyond chemotherapy. The impact of low PD-L1 would typically mean less likelihood of success with immunotherapy. Chemotherapy is often effective to an extent but may not result in a durable or complete response, particularly in advanced metastatic settings."
      },
      {
        "action": "Inner Thinking",
        "title": "Expectations for Overall Response",
        "content": "Given the advanced stage with brain metastases and lack of targetable mutations, the patientâ€™s response to the Pemetrexed/Cisplatin regimen might be partial response or stable disease. Complete responses are rare in this context with chemotherapy alone."
      },
      {
        "action": "Final Conclusion",
        "content": "The most likely treatment response for a 68-year-old male with brain metastasis, EGFR wild-type, ALK-negative, and PD-L1 0% when treated with Pemetrexed/Cisplatin chemotherapy is a partial response or stable disease."
      },
      {
        "action": "Verification",
        "content": "Reviewing common outcomes for patients with this profile, those treated solely with chemotherapies like Pemetrexed/Cisplatin often achieve partial responses. The presence of brain metastases and absence of targetable mutations further suggest this conclusion is plausible. Thus, the conclusion holds."
      }
    ]
  ],
  "response_type": [
    "Init_CoT"
  ],
  "prior_fail_try": [],
  "Complex_CoT": "Okay, so there's this 68-year-old guy dealing with adenocarcinoma which has unfortunately spread to his brain. That's definitely tough. Let's see, his tumor is EGFR wild-type and ALK-negative, which means those fancy EGFR or ALK inhibitors won't work for him. And his PD-L1 expression is 0%, so that tells us the immune checkpoint inhibitors might not be that effective here either. Hmm, not a lot of targeted therapy options available.\n\nAlright, let's think about chemotherapy then. Pemetrexed and cisplatin are pretty common for non-small cell lung cancer folks. They usually use these drugs when there aren't any specific targets to aim for and the person is in good health for treatment. But we have to consider the brain metastases situation, since chemotherapy doesn't always get through the blood-brain barrier effectively.\n\nGiven his molecular profile, we can't really rely on targeted or immune therapies, so chemotherapy might be our mainstay. Oh, right, and his low PD-L1 expression usually means limited success with immunotherapy. So, we're kind of sticking to chemotherapy, trying to manage what we can.\n\nGenerally, with cases like his, achieving a complete response is really rare. Chemotherapy could give him a partial response, you know, like shrink the tumor a bit or at least stop it from growing, or it might keep things stable for a while. There's some hope for improvement but not a cure with just this regimen.\n\nSo, after thinking through all of that, I'd say the most likely response for him with the Pemetrexed/Cisplatin treatment is partial response or maybe stable disease. Let's be honest here; given the spread and those molecular characteristics, we're looking at managing the disease more than anything else.",
  "Response": "Given the clinical profile described for the 68-year-old male with adenocarcinoma that has metastasized to the brain, along with his molecular characteristicsâ€”EGFR wild-type, ALK-negative, and PD-L1 expression at 0%â€”the most suitable treatment option in this scenario is a chemotherapy regimen, such as Pemetrexed/Cisplatin. Because this patient's cancer lacks actionable mutations or markers that would make targeted therapy or immunotherapy more effective, chemotherapy becomes the main course of action.\n\nThe anticipated response to the Pemetrexed/Cisplatin regimen, taking into account the extent of disease spread and the available treatment limitations, is most likely to be partial response or stable disease. This means that while the treatment may reduce tumor size or slow disease progression, achieving a complete response or cure with this approach is unlikely. The primary goal in this context is disease management, aiming to control tumor growth and maintain the patient's quality of life.",
  "Question": "Based on the clinical profile of a 68-year-old male patient with adenocarcinoma, brain metastasis, EGFR wild-type, ALK-negative, PD-L1 0%, and treated with the chemotherapy regimen of Pemetrexed/Cisplatin, what is the most likely treatment response observed?"
}